Take a look at the bold in paragraph three.
Thomas Pharmaceuticals Announces Corporate Reorganization and Business Outlook
Thomas Pharmaceuticals, Ltd. (OTCBB:TPHM) today announced that it had accepted the resignation of Mr. Jerry Mahoney as Non-Executive Chairman of the Company and John Lucas as Chief Executive Officer and Director. The Board has appointed Mark Meller as the new CEO and Chairman of the Board of Directors. Frank Esser will continue as a member of the Board of Directors and head of the Audit Committee.
Mr. Meller is currently CEO and a director of both MM2 Group, Inc. and Trey Resources, Inc. He is also a director of SpeechSwitch, Inc. From October 2004 until January 2007, he was also Chief Executive Officer and Director of Deep Field Technologies, Inc From August 2005 until August 2006, Mr. Meller served as Chief Executive Officer of iVoice Technology, Inc. Mr. Meller was also previously, for over 15 years, Chief Executive Officer of Bristol Townsend & Co., Inc., a New Jersey based consulting firm providing merger and acquisition advisory services to middle market companies. Mr. Meller is an attorney and a member of the Bar of the State of New York.
Mr. Meller stated, “I want to thank Mr. Mahoney and Mr. Lucas for their service to the company. In light of Mr. Mahoney’s substantial experience, I have asked him to stay on as a consultant to the company, where he will advise me on a host of corporate finance and acquisition related issues.” Mr. Meller continued, “Our immediate focus will be to increase shareholder value by implementing an acquisition. Towards that end, I will be investigating a host of potential transactions, including technology deals and deals in China, where I believe there is still tremendous growth and opportunity. I will also be working with investment banks to properly capitalize the company, so that we can move forward with a strong and solid balance sheet. I will be making announcements to our shareholders as these plans develop and evolve.” iVoice, Inc.(IVOI), distributed to the Company’s shareholders shares of common stock of its subsidiary Thomas Pharmaceuticals Ltd. This was the fifth common stock dividend issued by the Company to its shareholders including Trey Resources, Inc., (TYRIA) iVoice Technology (IVOT), Inc., SpeechSwitch (SSWC), Inc. and. DeepField Technologies, Inc.
Certain information included in this press release, may contain forward-looking statements about our current and expected performance trends, growth plans, business goals and other matters. These statements may be contained in our filings with the Securities and Exchange Commission, in our press releases, in other written communications, and in oral statements made by or with the approval of one of our authorized officers. Information set forth in this press release contains various "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. The Private Securities Litigation Reform Act of 1995 (the "Act") provides certain "safe harbor" provisions for forward-looking statements. The reader is cautioned that such forward-looking statements are based on information available at the time and/or management's good faith belief with respect to future events, and are subject to risks and uncertainties that could cause actual performance or results to differ materially from those expressed in the statements. Forward-looking statements speak only as of the date the statement was made. We assume no obligation to update forward-looking information to reflect actual results, changes in assumptions or changes in other factors affecting forward-looking information. Forward-looking statements are typically identified by the use of terms such as "anticipate," "believe," "could," "estimate," "expect," "intend," "may," "might," "plan," "predict," "project," "should," "will," and similar words, although some forward-looking statements are expressed differently. Although we believe that the expectations reflected in such forward-looking statements are reasonable, we can give no assurance that such expectations will prove to be correct.
AI
